Cortexyme

Cortexyme

Cortexyme

Cortexyme is developing novel treatments for altering the course of Alzheimer'sand other neurological diseases.
Type
B2c
Raised
$99.6M
Follow us
Alexa global traffic share
Latest funding Show all
Team Size
2
Employees
$76,000,000 Venture capital (Series B)
FinSMEs , PE HUB , MedCity News

Cortexyme Completes $76M in Series B Financing

Funding Health
$15,000,000 Venture capital (Series A)
FinSMEs

Cortexyme Raises $15M in Series A Financing

Funding Health